OncoMatch/Clinical Trials/NCT06084234
National Liver Cancer Screening Trial
Is NCT06084234 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies non-drug interventions for carcinoma, hepatocellular.
The National Liver Cancer Screening Trial is an adaptive randomized phase IV Trial comparing ultrasound-based versus biomarker-based screening in 5500 patients with cirrhosis from any etiology or patients with chronic hepatitis B infection. Eligible patients will be randomized in a 1:1 fashion to Arm A using semi-annual ultrasound and AFP-based screening or Arm B using semi-annual screening using GALAD alone. Randomization will be stratified by sex, enrolling site, Child Pugh class (A vs. B), and HCC etiology (viral vs. non-viral). Patients will be recruited from 15 sites (mix of tertiary care and large community health systems) over a 3-year period, and the primary endpoint of the phase IV trial, reduction in late-stage HCC, will be assessed after 5.5 years.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Lab requirements
Liver function
Cirrhosis from any etiology or chronic hepatitis B; Child Pugh C cirrhosis [excluded]
Cirrhosis from any etiology or chronic hepatitis B; Child Pugh C cirrhosis [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Southern California · Los Angeles, California
- Stanford University · Redwood City, California
- Kaiser Permanente · Roseville, California
- University of California, San Francisco · San Francisco, California
- Northwestern University · Chicago, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify